The Duke Consortium for Innovative HIV/AIDS Vaccine and Cure Research (CIAVCR) is a collaborative research program lead by researchers at Duke University, the University of Pennsylvania, the University of North Carolina Chapel Hill, and the Beth Israel Deaconess Medical Center.
![CIAVCR logo2](/sites/default/files/2023-10/ciavcr-logo-150p.png)
The proposed studies in the Duke CIAVCR program will contribute towards the ultimate goal of ending the HIV/AIDS epidemic. It has been four decades since the start of the HIV/AIDS epidemic and a protective vaccine or functional cure have been elusive. In 2020, there was an estimated 37.6 million people living with HIV. Despite highly active anti-retroviral therapies, approximately 500,000 new infections occur every year. Thus, finding a way to end this pandemic remains a global priority. The CIAVCR program will provide new insights into the effects of vaccine-induced polyfunctional immune responses in preventing HIV-1 infection as well as their potential therapeutic impact in eliminating HIV latent reservoirs.